Roth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff maintains a Buy rating on Aptevo Therapeutics but lowers the price target from $15 to $8.
September 23, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Roth MKM's analyst Jonathan Aschoff continues to recommend buying Aptevo Therapeutics stock but has reduced the price target significantly from $15 to $8, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in Aptevo's potential, but the lowered price target reflects a more conservative valuation, possibly due to market conditions or company performance. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100